140 related articles for article (PubMed ID: 2417118)
1. Expression of ras oncogene p21 in prostate cancer.
Viola MV; Fromowitz F; Oravez S; Deb S; Finkel G; Lundy J; Hand P; Thor A; Schlom J
N Engl J Med; 1986 Jan; 314(3):133-7. PubMed ID: 2417118
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
Purnell DM; Heatfield BM; Trump BF
Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical staining of ras p21: staining in benign and malignant prostate tissue.
Bushman EC; Nayak RN; Bushman W
J Urol; 1995 Jan; 153(1):233-7. PubMed ID: 7526005
[TBL] [Abstract][Full Text] [Related]
4. Comparative immunohistochemical study of ras-p21 oncoprotein in adenomatous hyperplasia and adenocarcinoma of the prostate gland.
Agnantis NJ; Constantinidou AE; Papaevagelou M; Apostolikas N
Anticancer Res; 1994; 14(5B):2135-40. PubMed ID: 7530930
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to ras oncogene p21 proteins lack immunohistochemical specificity for neoplastic epithelium in human prostate tissue.
Varma VA; Austin GE; O'Connell AC
Arch Pathol Lab Med; 1989 Jan; 113(1):16-9. PubMed ID: 2462857
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical detection of ras oncogene p21 product in liver cirrhosis and hepatocellular carcinoma.
Nonomura A; Ohta G; Hayashi M; Izumi R; Watanabe K; Takayanagi N; Mizukami Y; Matsubara F
Am J Gastroenterol; 1987 Jun; 82(6):512-8. PubMed ID: 3034055
[TBL] [Abstract][Full Text] [Related]
7. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
8. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
9. Ras p21 immunostaining in early stage squamous cervical carcinoma: relationship with lymph nodal involvement and 72 kDa-metalloproteinase index.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Nictolis MD; Romanini C; Biagini G
Anticancer Res; 1998; 18(1B):609-13. PubMed ID: 9568185
[TBL] [Abstract][Full Text] [Related]
10. Expression of ras oncogene p21 antigen in normal and proliferative thyroid tissues.
Johnson TL; Lloyd RV; Thor A
Am J Pathol; 1987 Apr; 127(1):60-5. PubMed ID: 3105323
[TBL] [Abstract][Full Text] [Related]
11. Immunoexpressions of p21, Rb, mcl-1 and bad gene products in normal, hyperplastic and carcinomatous human prostates.
Royuela M; Arenas MI; Bethencourt FR; Sánchez-Chapado M; Fraile B; Paniagua R
Eur Cytokine Netw; 2001; 12(4):654-63. PubMed ID: 11781193
[TBL] [Abstract][Full Text] [Related]
12. Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues.
Ohuchi N; Thor A; Page DL; Hand PH; Halter SA; Schlom J
Cancer Res; 1986 May; 46(5):2511-9. PubMed ID: 3084069
[TBL] [Abstract][Full Text] [Related]
13. c-met proto-oncogene expression in benign and malignant human prostate tissues.
Pisters LL; Troncoso P; Zhau HE; Li W; von Eschenbach AC; Chung LW
J Urol; 1995 Jul; 154(1):293-8. PubMed ID: 7539865
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.
Mizukami Y; Nonomura A; Noguchi M; Taniya T; Koyasaki N; Saito Y; Hashimoto T; Matsubara F; Yanaihara N
Anticancer Res; 1991; 11(4):1485-94. PubMed ID: 1660689
[TBL] [Abstract][Full Text] [Related]
15. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
16. CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator?
Ang J; Lijovic M; Ashman LK; Kan K; Frauman AG
Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1717-21. PubMed ID: 15533898
[TBL] [Abstract][Full Text] [Related]
17. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
Arai T; Fujita K; Fujime M; Irimura T
Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates.
De Miguel P; Royuela ; Bethencourt R; Ruiz A; Fraile B; Paniagua R
Cytokine; 1999 Sep; 11(9):722-7. PubMed ID: 10479409
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of carcinogenesis: the role of oncogenes, transcriptional enhancers and growth factors.
Spandidos DA
Anticancer Res; 1985; 5(5):485-98. PubMed ID: 3904595
[TBL] [Abstract][Full Text] [Related]
20. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer.
Fizazi K; Martinez LA; Sikes CR; Johnston DA; Stephens LC; McDonnell TJ; Logothetis CJ; Trapman J; Pisters LL; Ordoñez NG; Troncoso P; Navone NM
Clin Cancer Res; 2002 Mar; 8(3):775-81. PubMed ID: 11895908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
